Marijuana Inc. Stock Price, News & Analysis

Exousia Pro (OTCPINK: MAJI) announced that the FDA granted Orphan Drug Designation (ODD) for its exosome-based treatment for malignant glioma (Glioblastoma multiforme) on October 28, 2025. The ODD was filed by subsidiary Exousia AI with Dr. Marvin S. Hausman and is intended to advance the company's therapy into the next clinical phases.

The release notes that only 11% of ODDs are awarded at the preclinical stage and that the company plans to work with investment bankers to monetize the designation while continuing development. Management describes the technology as exosomes loaded with nucleic acids combined with standard anticancer therapy for GBM.

Exousia Pro (OTCPINK:MAJI) has announced plans for an IRB study to evaluate their innovative CBD-loaded exosome technology for edibles. The study will compare their proprietary exosome-based CBD gummies against standard formulations, focusing on bioavailability and plasma levels.

The company's technology utilizes exosomes as protective nano-carriers that shield CBD from digestive degradation, potentially solving a major challenge in the edibles market. The comparative trial is scheduled for Q4 2025, with participants testing both formulations through a series of blood draws to measure effectiveness.

President Matt Dwyer highlighted this as a significant opportunity, noting strong initial interest from potential partners in the US and Europe. The study aims to validate their technology's superiority and establish licensing opportunities in the cannabinoid and nutraceutical industries.

Exousia Pro (OTCPINK:MAJI), a clinical-stage biotechnology company, reported positive developments in its legal proceedings against former CEO Donald Steinberg and related shareholders. The company secured a standstill order on approximately 10.5% of outstanding shares held by the former CEO.

Additionally, Exousia Pro executed two rescission agreements blocking legend removal on 3,250,000 shares (approximately 8% of outstanding shares). While the Temporary Restraining Order hearing was not conducted, the company achieved significant shareholder protections through these legal measures.

The company plans to refocus on its core business of developing exosome-based cancer therapies and will provide updates on ongoing studies, therapies, and patents.

Exousia Pro (OTCPINK:MAJI) has filed a provisional patent (#63/877,517) for a novel method of loading Extracellular Vesicles (EVs), marking a significant strategic advancement in exosome-based therapies. The technology, to be utilized under the Exousia Health division, enhances the efficiency and stability of therapeutic agent delivery through exosomes.

The innovation targets three major markets with a combined value exceeding $2.7 trillion: the pharmaceutical market ($1.77 trillion), nutraceuticals market ($500 billion), and cosmetics market ($450 billion). The company is preparing to file trademarks for new products leveraging this technology, representing one of two patent-ready technologies currently in development.

Exousia Pro (OTCPINK:MAJI) announced its strategic entry into the telehealth market through an acquisition that will establish its new division, Exousia Health. The acquired telehealth company brings an initial base of 1,000 active clients and projected monthly revenue of $50,000.

The company is reviewing two additional significant contracts expected to boost monthly revenue substantially. Exousia Health also plans to integrate a compounding pharmacy operation, creating a third revenue stream by handling prescriptions from its telehealth doctors directly.

Management expects Exousia Health to become the company's primary revenue generator until its AI division begins licensing cancer therapy technology.

Exousia Pro (OTCPINK:MAJI), a clinical-stage biotech company, has announced the creation of three new divisions under a newly formed subsidiary, Exousia Pro Holding Management, LLC (EPHM). The divisions include Exousia Ai, Exousia Health, and Exousia Wholesale, each structured for independent growth and potential future spin-offs.

The company plans to file two new patents in September 2025 and is developing new products for a market currently valued at $8.7 billion, expected to reach $18.5 billion in the next decade. Exousia Health is preparing to enter a partnership giving access to 200,000 active patients for marketing subscription-based health products.

Exousia Pro (OTCPINK:MAJI), a clinical-stage biotech company, has filed a Regulation A offering to raise up to $4.985 million for various business initiatives. The company plans to allocate the funds across several key areas, with the largest portion ($2 million) dedicated to Investigational New Drug (IND) trials for Glioblastoma treatment.

The funding will also support new product development from mushroom exosomes ($1 million), potential acquisitions ($1.5 million), lab equipment ($250,000), marketing ($150,000), and working capital ($85,000). The company emphasizes a strategic approach to raising capital, planning to secure funds as needed to avoid excessive shareholder dilution.

Exousia Pro (OTCPINK:MAJI), a clinical-stage biotech company focused on exosome therapies for cancer and other diseases, has announced the expansion of its Scientific Advisory Board (SAB) with Dr. Marvin S. Hausman, MD as Chairman. The newly assembled SAB includes distinguished experts: Dr. Robert B. Beelman (Professor Emeritus of Food Science at Penn State), Dr. Kyle H. Ambert (Director of Data Science at Nike), Dr. Zachary T. Bitzer (Assistant Professor at Penn State), and Dr. Anthony Smith (natural product development expert). Dr. Hausman brings over 40 years of drug research experience and has served in leadership roles at companies like Bristol Myers International and Ludwig Enterprises. The advisory board will guide Exousia Pro's expansion into new areas with plant-based exosomes.

Exousia Pro announces the addition of Dr. Marvin Hausman as a consultant and the launch of a new weekly web series titled "Ask Dr. Hausman." The clinical-stage biotech company, trading as MAJI on OTCPINK, focuses on developing exosome-based therapies for cancer and other diseases.

Dr. Hausman, who played a key role in creating Exousia AI and establishing the Glioblastoma study with UCF, will host the series where shareholders can submit questions. The program will cover updates on ongoing studies, FDA submissions, and future IND trials.

Company President Matt Dwyer highlighted Dr. Hausman's valuable network of scientific and financial professionals in the biotech sector, expressing confidence that this collaboration will open new opportunities for Exousia Pro's advancement in plant-based exosome therapies.